GSK to cut prices in emerging markets – CEO

Guardian

United Kingdom
LONDON, June 12 (Reuters) – British pharmaceutical firm GlaxoSmithKline is planning to cut the prices of many of its leading medicines in emerging markets, CEO Andrew Witty said in an interview with the Financial Times.
“Making sure the price-volume equation is right is a key piece of the strategy,” Witty was quoted as saying in the paper’s Friday edition.
The plan follows the success of a pilot programme in the Philippines, the paper said. Speaking from the Philippines, Witty said a 60 percent cut in the local price of its cervical cancer vaccine Cervarix had increased sales eightfold. (Reporting by Rosalba O’Brien; Editing by Gary Hill)
Comment from Leslie
Well, GSK is not cutting  prices in Jamaica where they are charging $7,500 per dose – Come on people this is called marketing – sell by volume – get those numbers up for the stockholders.  Remember when the tobacco companies gave away free cigarettes?
PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.